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Obesity is a common risk factor for non-alcoholic fatty liver disease (NAFLD). Currently,
there are no specific treatments against NAFLD. Thus, examining any molecule with poten-
tial benefits against this condition emerged melatonin as a molecule that influences meta-
bolic dysfunctions. The aim of this study was to determine whether melatonin would
function against NAFDL, studying morphological, ultrastuctural and metabolic markers that
characterize the liver of ob/obmice.
Methods
Lean and ob/obmice were supplemented with melatonin in the drinking water for 8 weeks.
Histology and stereology were performed to assess hepatic steatosis and glycogen deposi-
tion. Ultrastructural features of mitochondria, endoplasmic reticulum (ER) and their juxtapo-
sitions were evaluated in livers of all experimental groups. Furthermore, hepatic distribution
and expression of markers of ER and mitochondria (calnexin, ATP sintase β, GRP78 and
CHOP) and metabolic dysfunction (RPB4, β-catenin) and cellular longevity (SIRT1) were
analyzed.
Results
Melatonin significantly reduced glycemia, identified also by a decrease of hepatic RBP4
expression, reversed macrosteatosis in microsteatosis at the hepatic pericentral zone,
enlarged ER-mitochondrial distance and ameliorated the morphology and organization of
these organelles in ob/obmouse liver. Furthermore, in ob/obmice, calnexin and ATP
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synthase β were partially restored, GRP78 and CHOP decreased in periportal and midzonal
hepatocytes and β-catenin expression was, in part, restored in peripheral membranes of
hepatocytes. Melatonin supplementation to ob/obmice improves hepatic morphological,
ultrastructural and metabolic damage that occurs as a result of NAFLD.
Conclusions
Melatonin may be a potential adjuvant treatment to limit NAFLD and its progression into irre-
versible complications.
Introduction
Obesity is a worldwide epidemic and the fifth leading cause of death [1]. Obesity negatively
impacts the function of many organs including cardiovascular and metabolic systems [2].
Moreover, obesity is a common well-documented risk factor for non-alcoholic fatty liver dis-
ease (NAFLD). This latter condition is a chronic liver disease, which includes a spectrum of
hepatic pathologies and can involve cirrhosis. Moreover, NAFLD is characterized by macroves-
cicular steatosis and hepatocyte ballooning. These alterations are similar to those observed in
alcoholic liver disease in humans even if they occur in the absence of alcohol consumption [3].
The liver is mainly involved in NAFLD because it functions in glycogen deposition, fatty acid
oxidation, cholesterol transport and modulation of bile flux [4,5]. In particular, the endoplas-
mic reticulum (ER) of hepatocytes plays an important part in fatty acid synthesis and choles-
terol metabolism. The relationship between ER stress and fatty liver is a bilateral one: steatosis
has been shown to promote ER stress and, conversely, the ER stress response leads to steatosis.
Current evidence strongly supports an important role for ER stress in NAFLD [6].
Globally, NAFLD affects numerous people around the world; its frequency is increasing
possibly due to changes in dietary habits and the common prevalence of sedentary lifestyles
[7,8]. Current, NAFLD treatments involve correcting diet, exercise and drugs, including met-
formin, statins and fibrates. However, these drugs have a variety of adverse effects or contrain-
dications and there is still no consensus on the most effective drug therapy for NAFLD [9].
Therefore, new candidates, such as active endogenous molecules with high efficiency and mini-
mal side effects are urgently needed for the treatment of NAFLD.
Retinol binding protein 4 (RBP4) is produced in different tissues, including adipose tissue,
liver and muscles. Mansouri et al. [10] reported that increased serum level of RBP4 in diabetic
rats might be a consequence of its elevated mRNA and protein expression in the liver and adi-
pose tissue, with the highest expression level in the liver followed by adipose tissue. Moreover,
circulating RBP4 is elevated in obese subjects compared to lean individuals. Additionally,
RBP4 mRNA in visceral and subcutaneous abdominal adipose tissue is higher in obese patients
compared to lean subjects [11].
Calnexin (CNX) is a 90-kDa type I integral ER transmembrane chaperone that transiently
binds newly-synthesized monoglucosylated and misfolded glycoproteins, promoting their fold-
ing and oligomerization [12,13]. ATP-synthase subunit β (ATPSβ) is a novel biomarker of
mitochondrial dysfunction. More recently, it has been demonstrated its role in regulation of
hepatic ATP content and glucose metabolism in diabetic mice. ATPSβ expression and ATP
content were both reduced in the liver of type 1 and type 2 diabetic mice [14].
G protein-coupled receptor (GRP78), the master resident ER chaperone, and its down-
stream target CCAAT/enhancer binding protein-α (C/EBP) homologous protein (CHOP) are
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involved in the development of NAFLD in obese animal models and patients [15,16]. In partic-
ular, the mitochondria associated membranes area (MAM), a subdomain of the ER, is crucial
for lipid transfer, regulation of mitochondrial shape and modulation of ER stress in metabolic
human diseases [17].
Sirtuins (SIRTs) are enzymes with NAD+-dependent class III histone deacetylase activity
that regulate longevity and metabolism in mammalians [18–20]. SIRT1 limits obesity by
enhancing fatty acid oxidation and mitochondria biogenesis due to interaction with prolifera-
tors-activated receptor coactivator-1α (PGC-1α) [21].
Beta-catenin (β-catenin), an indicator of hepatic metabolism is involved in regeneration,
resistance to hypoxia, apoptosis, steatosis, modulation of zonation and cholesterol metabolism
[22,23]. Consequently, β-catenin signaling is essential for an optimum hepatic homeostasis.
Further, it has been demonstrated that its dysregulation is evident in aberrant hepatic growth
during various liver tumors [24].
Melatonin, an indoleamine derived from L-tryptophan and secreted from pineal gland,
shows a wide range of physiological and pharmacological functions including beneficial effects
in metabolic diseases and their cardiovascular complications [25–28]. Exogenous melatonin
supplementation is safe and, due to its amphipathic nature, easily penetrates into every subcel-
lular site. Furthermore, melatonin maintains biological membrane fluidity and it acts as an
antioxidant and reactive oxygen species (ROS) scavenger also at the mitochondrial level [29].
Moreover, it counteracts adipogenesis by stimulating thermogenesis, insulin sensitivity, glucose
uptake and ameliorating liver functions in different metabolic and physiological conditions
[30]. Recent studies reveal that melatonin directly regulates metabolic parameters in experi-
mental and clinical studies [30–33], restores sleep rhythm in obese patients [34] and the hor-
monal flux in high fat diet rodents [35]. Nevertheless, melatonin effects are linked to circadian
rhythm, dose, administration route and the presence of specific receptors [36]. Indeed, melato-
nin improves hepatosteatosis, but does not reduce liver weight when intra-peritoneally admin-
istered in ob/obmice at 18 weeks of age [37]. Although, numerous papers showing that
melatonin is associated with reduction of adiposity and body mass [30], its roles and its action
mechanisms are not fully understood. Thus, the aim of this study was to determine how mela-
tonin might act as a potential therapeutic tool for this health problem. For this purpose, we
used ob/obmice, which have a defect in leptin synthesis and reproduces many of the metabolic
disturbances present in NAFLD patients [38] which allowed us to investigate the effects of mel-
atonin administration on liver morphology and function. Herein, we considered and evaluated
a variety of markers listed above involved in metabolic functions, oxidative stress and cellular
longevity of hepatocytes. Our results indicate that melatonin administration to ob/obmice
improves hepatic morphological and metabolic damages determined by NAFLD that are rising
because of an increasing prevalence of obesity and metabolic syndrome [39].
Materials and Methods
Experimental design
The experiments were conducted according the National Ministerial guidelines, minimizing
any sufferance. In particular, the experimental animal project was approved by the Committee
for the Care and Use of Animals of the University of Brescia, Italy and by the Italian Ministry
of Health. 40 male mice at 4 weeks of age grouped included 20 lean (B6.V-(lean)/Ola Hsd) and
20 obese leptin-deficient animals (B6.V-Lepob/OlaHsd), purchased from Harlan Laboratories
S.r.l., Udine, Italy, were studied. Animals were housed in an approved facility with 12h dark/
12h light and constant temperature with a standard rodent diet provided ad libitum. The ani-
mals received, for 8 weeks from 5th to 13th week, of life supplemented vehicle or melatonin
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dissolved in drinking water at the final dose of 100 mg/kg/day. These dose and duration of mel-
atonin treatment had previously been shown to improves glucose homeostasis by restoring the
vascular action of insulin in a study of Sartori et al.[40]. Melatonin was dissolved in 1% ethanol
and diluted in drinking water. Fresh melatonin and vehicle solutions were prepared twice a
week and the melatonin content was adjusted to the body weight of individual animals
throughout the study period. Body weight, water consumption and blood glucose were regu-
larly monitored, as describe in detail in the following paragraph. At the end of the treatment,
mice were sacrificed by cervical dislocation and liver was removed and fixed in buffered forma-
lin for 24 hours and embedded in paraffin wax for histological and immunohistochemical
stainings or fixed in 2.5% glutaraldehyde in 0.1M cacodilate buffer, post-fixed in osmium
tetroxide and embedded in Epon resin for ultrastructural analysis or properly homogenized
and then processed for the enzyme-linked immunosorbent assay (ELISA).
More details on chow composition, food intake and metabolic parameters have been
reported in our previous studies [25,31,41].
Body weight and blood glucose evaluation
Body weight was measured twice a week, before melatonin replace, always at the same time of
day and body weight gain was calculated as the difference between body weight measured at
the beginning and at the end of all the period of treatment. Furthermore, blood glucose was col-
lected via tail-snip and measured using a glucose test strip reader.
Histological analyses
Paraffin sections (7μm thick) cut with a microtome were collected on poly-D-lysine-coated
slides, deparaffinized, rehydrated and stained using haematoxylin or PAS for histopathological
analysis. Steatosis was assessed on hematoxylin-eosin stained sections by counting randomly
chosen 200 lipid droplets/groups and selecting their diameter (μm), area (μm2) and volume
density (%) at a final magnification of 400X in pericentral hepatocytes. PAS positive glycogen
and glycoproteins inside hepatocytes was estimated according to hepatic zonation at final mag-
nification of 200X and expressed as arbitrary units (AU). The morphometrical analyses were
performed by two different observers blinded to the experimental group, using a computer
image analysis software (Image J-Image Processing and Analysis in Java).
Immunohistochemical analysis
Paraffin sections of liver were deparaffinized, rehydrated and subjected to antigen retrieval in
0.01M sodium citrate buffer (pH 6.0) in a microwave oven and then the sections were treated
in 3% hydrogen peroxide to block endogenous peroxidase activity. The sections were incubated
then with normal serum from species producing the secondary antibody and subsequently
with primary polyclonal antibodies against SIRT1, GRP78 and CHOP (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), diluted 1:150, 1:300 and 1:50 respectively and monoclonal antibod-
ies against β-catenin (BD Transduction, San Jose, CA, USA) and RBP4 (Abcam, Cambridge,
UK), diluted 1:50 and 1:100 respectively. After washing in tris buffered saline (TBS), specific
secondary antibodies were applied and then incubated in avidin-biotin-peroxidase complex
according to manufacturer instructions (ABC-peroxidase kit Vector Labs, Burlingame, CA,
USA). Finally, the sections were incubated in a solution of 0.05% 3–3’-diaminobenzidine tetra-
hydrochloride (Sigma Aldrich, St. Louis, MO, USA) and 0.33% hydrogen peroxide [42,43]. All
sections were finally counterstained with haematoxylin, dehydrated and mounted. Negative
controls were performed by omitting the primary antibody step.
Non-Alcoholic Fatty Liver Disease and Melatonin
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Immunostaining intensity, expressed as arbitrary units (AU) or percentage of immunoposi-
tive nuclei, was evaluated by two observers blinded to the specific experimental group. 20 ran-
dom fields with the same area were estimated using an image analyzer (Image Pro Plus, Milan,
Italy).
Sirtuin1 ELISA assay
Liver contents of SIRT1 was measured using a commercial mouse ELISA kit (AbCam, Cam-
bridge, UK), according to manufacturer’s guidelines. In particular, the optical density was
determined at 450 nm in a microplate reader and the SIRT1 levels were expressed as ng/ml.
Immunofluorescence analysis
Deparaffinized and rehydrated sections were incubated in citrate buffer for 10 minutes in a
microwave oven to reveal antigens. After washings in TBS, sections were incubated with 10%
normal goat serum (Abcam, Cambridge, UK) with 1% bovine serum albumine for an hour at
room temperature. This was followed by an overnight incubation at 4°C within the following
primary antibodies: calnexin and ATPSβ (both diluted 1:100; Abcam, Cambridge, UK). After
washings in TBS with 0.1% Tween-20 (TBS-T), sections were labeled with appropriate fluoro-
chrome-conjugated secondary antibody mixture. Calnexin was labeled with Alexa Fluor 488
secondary antibody (diluted 1:400; Life Technologies, Carlsbad, CA, USA) and ATPSβ was
labeled with Alexa Fluor 633 antibody (diluted 1:400; Life Technologies, Carlsbad, CA, USA).
After, the slides were counterstained with the nuclear stain propidium iodide (diluted 1:1000;
Sigma Aldrich, Seelze, Germany) for 5 minutes. As a final step, slides were washed in TBS and
mounted with Mowiol (Sigma Aldrich, Seelze, Germany). Confocal images were acquired with
Leica TCS SP5 II microscope (Leica Microsystems, Wetzlar, Germany) in sequential mode to
avoid crosstalk between channels. The double stained sections were excited with 488 and 633
nm lasers, respectively. Nuclei were visualized using 543 nm laser and blue false-colored for
clear distinction of green/red channels. Negative controls were performed by the omission of
primary antibodies. Immunofluorescence intensity, expressed as percentage of immunopositiv-
ity normalized to lean value, was determined using a LAS AF software (Leica Microsystems,
Wetzlar, Germany), by two observers blinded to the specific experimental group.
Transmission electron ultrastructural analysis
Semithin (1μm-thick) sections cut with an ultramicrotome (Ultacut E- Leica, Microsystems S.r.
l., Milan, Italy) usung a diamond glass were collected, stained by toluidine blue and examined
by light microscopy at 1000x using an immersion oil-objective to detect macrosteatosis and
microsteatosis (Liquori et al., 2009). For ultrastructural analysis, thin (80 nm-thick) sections
obtained from periportal zone 1 and pericentral zone 3 were collected on 200 meshes-formvar
coated copper grids, double stained with uranyl acetate and lead citrate and photographed
using FEI Tecnai G2 Spirit or CM12 TEM transmission electron microscopes (FEI Instrumen-
tation Company, Eindhoven, The Netherlands) at 80kV. Evaluation of ER-mitochondria dis-
tance and mitochondria distribution was performed at pericentral zone 3 level [44].
Mitochondrial diameter was calculated, by two blinded observers, as the average diameter
per mitochondrion and 250 mitochondria per group were randomly selected. All above data
were measured on digital photomicrographs at final magnification of 15.000X with the aid of
an image analysis software (Image J- Image Processing and Analysis in Java). Moreover, fifty
ER-mitochondria distance were randomly chosen for each group by two blinded investigators
unaware of the experimental group. Further, mitochondria-ER distance were observed at
135.000X by a “Veleta” camera (Olympus Soft Imaging Solutions, Munster, Germany) and
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measured by an Olympus Soft Imaging System (iTEM FEI 5.1.30), by two different observers
blinded to the specific experimental group.
Statistical evaluation
Data were pooled as mean values ± standard errors. The ANOVA corrected by Bonferroni test
was used to determine differences between groups comparing the internal variability of group
with the variability among all experimental groups. A p<0.05 was considered statistically sig-
nificant. All assays were performed in triplicate, data were randomly collected and the analyses
were performed using OriginPro 9.1 software.
Results
In this study, ob/obmice treated with melatonin were compared with ob/ob animals and with
lean mice treated or not treated with melatonin. In our previous reports [25,31,41], we pub-
lished the food and weekly water intake values of these experimental groups. Herein, we report
only metabolic parameters, including body weight, mass gain, total water consumption and
blood glucose concentration, these data indicate the general health condition of also melatonin
treated experimental groups and underline that there are no side effect of melatonin supple-
mentation. In detail, body weights were significantly higher in ob/ob compared to that in con-
trol animals. Moreover, we observed a reduction of body weight in ob/obmice treated with
melatonin, although it was not significant. These observations were confirmed also by the body
weight gain observed from the 5th to 13th week of life (8 weeks of treatment), that was signifi-
cantly higher in ob/obmice respect lean mice treated and not treated with melatonin and
decreased a bit (not significantly) after melatonin supplementation. Furthermore, ob/obmice
had a total water consumption significantly higher respect lean mice and melatonin adminis-
tration decreased significantly water consumption in obese treated mice. In contrast lean mice
treated with melatonin did not modify water intake throughout the treatment period, as con-
firmed also by water weekly consumption showed in our previous study [25]. Melatonin sup-
plementation in obese mice also reduced significantly blood glucose to about 300–350 mg/dl vs
400 mg/dl of the hyperglycemic ob/obmice (p<0.05). Glycemic value was significantly higher
with respect control mice treated and not treated with melatonin, which had glucose concen-
trations less than 200 mg/dl. All these reported above data are summarized in Tables 1 and 2.
Furthermore, lean animals treated or not treated with melatonin had similar both weight and
glucose levels, so we refer to both animal groups as “control”.
In the hepatic parenchyma, metabolic functions are located heterogeneously in the peripor-
tal (comprising hepatocytes surrounding the distal branches of the portal vein) and pericentral
Table 1. Body weight andmass gain of each experimental groups.
Body weight (g) Body weight gain (%)
5 ws 9 ws 13 ws 5–13 ws
Lean 23.8±0.63 28.8±0.16 30.8±0.16 22.73
Lean + MEL 23.9±0.27 27.8±0.36 31±0.27 22.91
ob/ob 24.8±0.26 48.3±0.31 * + 54.2±0.09 * + 54.24 * +
ob/ob + MEL 24.1±0.29 46.2±0.27 * + 51.9±0.25 * + 53.57 * +
The values are expressed as mean values ± standard errors.
* p<0.05 vs lean mice
+ p<0.05 vs lean mice treated with melatonin.
doi:10.1371/journal.pone.0148115.t001
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(comprising hepatocytes surrounding the proximal branches of the central vein) zones of the
liver lobule [45]. Liver zonation is fundamental for proper functioning of this organ [46]. In
rodents and humans three zones of equal width, extending from the portal area (Glisson’s
sheath) to the central vein, are distinguished: zone 1-periportal, zone 2-intermediate, zone
3-pericentral [47]. The lobular pattern, with the central vein in the centre and the portal triads
in the periphery, was clearly evident in all experimental groups. The control mice showed a
radially arranged rays of hepatocytes, regularly directed from the central vein of each lobule
towards its periphery. In particular, the morphological analysis of the liver showed significantly
fat droplets deposition in ob/obmice respect control group, clearly localized in the pericentral
area (zone 3) of liver lobules, resulting in enlarged fat-laden hepatocytes, evaluated in detail in
this study. The same hepatic zone was greatly associated with steatosis also in adult patients
with NAFLD [48].
To better evaluate the role of glycemic value in ob/obmice, we studied also RBP4 expression
which is linked to blood glucose concentration [10]. Interestingly, RBP4 immunostaining was
mainly located in pericentral zone 3 of the lean liver and it was essentially undetectable in
other lobular zones of control mice (Fig 1A). In contrast, in ob/obmice showed an extensive,
significative and strong RBP4 signal diffusely distributed in every lobule from periportal zone 1
to pericentral zone 3 both at the nuclear and cytoplasmic level (Fig 1B). Remarkably, after
Table 2. Water consumption and blood glucose concentration of each experimental groups.
Total water consumption (ml/8 ws) Glucose concentration (mg/dl)
5–13 ws 5 ws 9 ws 13 ws
Lean 218.8±0.38 178±2.8 176±1.89 187±2.93
Lean + MEL 221.76±0.32 178±3.9 179±2.46 185±4.09
ob/ob 512.16±0.21 * + 255±3.22 * + 376±1.86 * + 391±1.61 * +
ob/ob + MEL 425.92±0.36 * +# 252±3.2 * + 307±1.48 * + # 341±3.11 * +#
The values are expressed as mean values ± standard errors.
* p<0.05 vs lean mice
+ p<0.05 vs lean mice treated with melatonin
# p<0.05 vs ob/ob mice.
doi:10.1371/journal.pone.0148115.t002
Fig 1. Liver RBP4 immunostaining.Hepatic immunostaining for RPB4 in lean (A), ob/ob (B) and ob/ob treated with melatonin (C) mice. Scale bars: 20 μm.
(v) identifies hepatic centrolobular vein.
doi:10.1371/journal.pone.0148115.g001
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melatonin supplementation in ob/obmice, RBP4-immunoreaction was significatively restricted
to pericentral hepatocytes, mainly in the cytoplasm where the staining was weak (Fig 1C).
After observing that treatment of ob/obmice with melatonin resulted in a reduction of the
parameters listed above, we investigated morphological and ultrastructural features of the liver.
Haematoxylin staining of the liver in control mice showed normal cytoarchitecture of the
parenchyma and periportal hepatocytes with occasional steatosis (less than 10%-grade 1). In
contrast, in ob/obmice, significative hepatocyte ballooning and extensive steatosis was evident
in every lobular zone, but mainly in the midzonal area where it appeared as a mixture of
macrosteatosis and microsteatosis (Fig 2A). When quantified, in obese liver more than 85% of
hepatocytes were filled with lipids (steatosis grade 3). By contrast, in ob/obmice treated with
melatonin, macrosteatosis shifted to microsteatosis with 45% of the hepatocytes exhibiting
steatosis (grade 2), so with a significant decrease of macrosteatosis (Fig 2B). This trend was
confirmed by detailed quantitative analysis of hepatosteatosis expressed as lipid droplet volume
density, diameter and area (Fig 2C–2E). Moreover, the measurement of glycogen deposition,
shown in Fig 3F, was moderate in periportal and pericentral hepatocytes of control mice,
intense in ob/obmice and significantly attenuated by melatonin supplementation.
Transmission electron microscopic observations revealed “normal” hepatocytes and regu-
lar-shaped organelles in the control mice. In particular, the mitochondria appeared with regu-
lar cristae encircled by short ER cisternae (Fig 3A and 3B). On the contrary, the ob/ob
hepatocytes were largely filled with lipid droplets, so mitochondria were restricted in a narrow
rim beneath the plasma membrane. Lipid droplets of different sizes sometimes presented a
dense osmophilic content. Mitochondria were heterogeneous in size and shape, with a greater
diameter respect controls and they were often seen as clusters with a dense matrix devoid of
inclusions and with short cristae. In ob/obmice the elongated rough ER (RER) cisternae were
closely associated with mitochondria and a significantly reduce distance between ER and
Fig 2. Liver lipid droplets and glycogen.Hepatic histological staining of ob/ob (A) and ob/ob treated with melatonin (B), showing macrosteatosis and
microsteatosis respectively. Haematoxylin staining. Scale bars: 20 μm. The graphs summarized the morphometrical analyses of lipid droplet volume density
(C), diameter (D) and area (E) and PAS glycogen intensity (F). * p<0.05 vs lean mice and # p<0.05 vs ob/obmice.
doi:10.1371/journal.pone.0148115.g002
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mitochondria was observed respect the control mice, underlining an abnormal increase in
MAM formation (Fig 3C and 3D). In ob/obmice treated with melatonin, hepatocytes in peri-
central and midzonal area contained significantly fewer lipid droplets, so mitochondria
occurred also in the perinuclear area. In particular, in the pericentral zone 3 round mitochon-
dria with short peripheral cristae and elongated types with a reduced diameter and an irregular
profile were observed. RER was well organized often in short and regular cisternae and
enlarged, compared with ob/obmice not melatonin treated, and the mitochondria were less fre-
quently attached to ER respect mitochondria collected from obese mice (Fig 3E and 3F). Quan-
titative analysis of the mitochondrial diameter (Fig 3G) and of the distance between ER and
mitochondria (Fig 3H), an indirect marker of MAM, taken together with ultrastructural evalu-
ation indicate that obesity leads to significant alterations in hepatic mitochondria and ER struc-
ture and enhance MAM formation, as confirmed also by Arruda et al. [55].
To confirm whether ER and mitochondria were involved in alterations of hepatic paren-
chyma, immunofluorescence analysis of CNX, ATPSβ, GPR78 and CHOP was performed. In
detail, we demonstrated an intense and significant positive staining of CNX and ATPSβ in con-
trol mice, that was significantly attenuated in ob/obmice and partly, but meaningful recovered
by melatonin. These results were summarized in Fig 3I and 3L, respectively. Moreover, we ana-
lyzed the distribution in hepatocytes of specific ER stress markers: GRP78 and CHOP. Espe-
cially in zone 2, GRP78 cytoplasmic staining intensity was moderate in control mice (Fig 4A),
Fig 3. Hepatic mitochondria and endoplasmic reticulum. Transmission electron microscopy photomicrographs of lean (A, B), ob/ob (C, D) and ob/ob
treated with melatonin mice (E, F) showed hepatic mitochondria and endoplasmic reticulum in all experimental groups. The white boxes identify the
mitochondria-endoplasmic reticulum contact. Scale bars: 500 nm for A and E; 200 nm for B, D and F and 1 μm for C. The graphs summarized the
morphometrical analyses of mitochondrial diameter (G), mitochondrium-endoplasmic reticulum distance (H) and of immunostaining evaluation for calnexin (I)
and ATP synthase β (L). * p<0.05 vs lean mice and # p<0.05 vs ob/obmice.
doi:10.1371/journal.pone.0148115.g003
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almost doubled, so significantly express, in ob/obmice (Fig 4B) and significantly decreased
after melatonin supplementation (Fig 4C); as confirmed and then summarized in Fig 4D. No
nuclear positivity was observed for GRP78, whereas we observed a moderate nuclear CHOP
immunostaining in control mice, strong, diffuse and significant in mid-zonal hepatocytes of
ob/obmice and weak and limited in ob/ob plus melatonin mice, so significantly reduced respect
obese mice not treated. The percentage of CHOP positive nuclei was less than 4% in control
mice, enhanced to 15% in ob/obmice and decreased to 7% after melatonin intake, thus showing
significant difference between ob/obmice treated and not with melatonin respect controls and
between obese mice treated with melatonin compared with untreated ob/ob animals (Fig 4E).
Based on these observations and to best correlate the morphological changes, the protective
role of melatonin on hepatic parenchyma alterations and the related underlying mechanisms,
we analyzed different markers involved in cellular longevity and hepatic metabolism: SIRT1
and β-catenin. Regarding SIRT 1 expression, we demonstrated that SIRT1 was detected in
nuclei of lobular zone 3 and zone 1 axis at a moderate level in control mice (Fig 5A). In con-
trast, in obese mice, SIRT1 immunoreaction was significantly barely detectable in the nuclei of
hepatocytes of the same areas (Fig 5B). After melatonin supplementation an evident and mean-
ingful signal was restricted to the nuclei of in pericentral zone 3 hepatocytes (Fig 5C). This data
also were confirmed by quantitative evaluation of SIRT1 nuclear immunoassaying (Fig 5D)
and, importantly, also by the quantitative measurement of SIRT1 protein level in tissue homog-
enate (Fig 5E).
Fig 4. Liver GRP78 and CHOP immunostainings.Hepatic immunostaining for GRP78 in lean (A), ob/ob (B) and ob/ob treated with melatonin (C) mice.
Scale bars: 20 μm. (v) identifies hepatic centrolobular vein. The graphs summarized the immunostaining evaluation for GRP78 (D) and nuclear CHOP (E). *
p<0.05 vs lean mice and # p<0.05 vs ob/obmice.
doi:10.1371/journal.pone.0148115.g004
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To better evaluate metabolic changes in the liver of ob/obmice, we studied also β-catenin. In
control mice, β-catenin signal was moderately to strongly expressed at the boundary of hepato-
cytes in the pericentral zone 3 (Fig 5F). In contrast, in ob/obmice, β-catenin immunoreaction
was significantly weak and sometimes barely detectable (Fig 5G). However, in ob/obmice
treated with melatonin, β-catenin immunopositivity was partially, but significantly, recovered
in pericentral zone 3 hepatocytes showing a moderate expression (Fig 5H).
Discussion
The results show that melatonin effectively reduces hepatic damage caused by NAFLD as
related to obesity and metabolic syndrome. These improvements were evaluated at morpholog-
ical and metabolic levels. In particular, we demonstrated that melatonin reduced body weight,
Fig 5. Liver SIRT1 and β-catenin immunostainings.Hepatic immunostaining for sirtuin 1 (A-C) and β-catenin (F-H) in lean (A, F), ob/ob (B, G) and ob/ob
treated with melatonin (C, H) mice. Scale bars: 20 μm. (v) identifies hepatic centrolobular vein. The graphs summarized the sirtuin 1 immunostaining
evaluation (D) and quantitative protein concentration in liver homogenate (E). * p<0.05 vs lean mice and # p<0.05 vs ob/obmice.
doi:10.1371/journal.pone.0148115.g005
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blood glucose and macrosteatosis in ob/obmice. In particular, in fatty liver of ob/obmice, lipid
droplets are large and filled with triglycerides, reducing fatty acid oxidation and alterating
microcirculation as reported by El-Badry et al. [49]. As already documented, melatonin plays a
vasculoprotective role and it has a beneficial effect by presumably forcing hepatocytes toward
fatty acid oxidation and microsteatosis [31]. These findings are in line also with those of Solís-
Muñoz et al. [38], who reported a similar trend in ob/obmice intraperitoneally treated with
melatonin at 10 mg/kg for 12 weeks [49].
Regarding the finding of increased in blood glucose concentration, we studied also the
expression of RBP4, which is a blood circulating adipokine. We observed an increase in its
expression in liver of ob/obmice. We suggest that the enhanced expression could be linked to
the rise in the glycemic value and may be a signal for the development of systemic insulin resis-
tance. This suggestion is in agreement with other papers showing the increased levels of RBP4
obtained both in experimental animals and in humans [50]. This author suggested that, in
mice, elevated levels of serum RBP4 led to impaired glucose uptake into muscle and induced
glucose production by liver; whereas lowered serum RBP4 levels greatly enhanced insulin sen-
sitivity. Thus, there is a possible link between obesity, glycemic value and insulin resistance.
Further, in the current study we show that melatonin ameliorated this situation. On the basis
of the these data, we suggest that melatonin regulates glucose production and determines its
optimal production in both the liver and in the blood.
Herein, we characterized, by transmission electron microscopy analyses, the organization of
mitochondria and RER and their physical distance from one another in ob/obmice treated or
not with melatonin. Melatonin reorganized RER and mitochondria mainly into round small
mitochondria instead of megamitochondria, with a greater diameter, in the pericentral area of
liver. Moreover, we demonstrated that melatonin expanded the strict juxtaposition between
RER and mitochondria in the hepatocytes of ob/ob liver, by restoring the right distance as in
control livers. This crucial ultrastructural finding may indicate the recovery of RER-mitochon-
dria interplay, that was in line with reduced hepatic lipid accumulation and macrosteatosis.
Indeed smooth or RER tethering to mitochondria is crucial for proper calcium flux from ER to
mitochondria and for lipid deposition [51]. Increased MAM formation drives higher calcium
accumulation in the mitochondria that in turn leads to impairment in mitochondrial oxidative
capacity, increased ROS generation, cellular stress, impaired insulin action in the liver and
abnormal glucose metabolism [52].
To confirm the involvement of ER and mitochondria in NAFLD, we studied also CNX,
ATPSβ, GPR78 and CHOP by immunofluorescence. We observed an intense CNX positivity in
ob/obmice which is reduced with melatonin. This suggests an interaction of melatonin with
CNX which determines calcium homeostasis. This data is in agreement with the finding of
Macías et al. [53] who demonstrated that melatonin binds to calreticulin, another stress protein
and its binding is very specific. In particular, calreticulin is a ubiquitous Ca2+ (calcium)-binding
protein of the ER that may be regulated through intracellular signaling pathways involving Ca2+
binding. This protein, like CNX, is multifunctional and plays an important role in the modula-
tion of a variety of cellular processes. These functions include chaperon activity, control of intra-
cellular Ca2+ homeostasis and regulation of cell adhesiveness by interacting with the integrins at
the cytoplasmatic site of the plasma membrane. Moreover, a recent paper reported that CNX is
an integral ER membrane protein and molecular chaperone involved in the folding and quality
control of membrane associated and secreted proteins, including many cell surface receptors
regulated by tyrosine phosphorylation [54]. This protein crosses the ER membrane with a por-
tion of the C-terminal domain residing in the cytoplasm where it may play a role in substrate
folding. The C-terminal domain undergoes post-translational modifications including palmi-
toylation. Palmitoylation of the C-terminal domain mediates its association with the ribosome-
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translocon complex inducing the association of CNX with the mitochondria associated region
of the ER. This post-translational modification indicates that the C-terminal domain of CNX
plays a functional role in linking ER lumenal events with cytoplasmic signaling.
With regard to ATPSβ, we found a low expression in obese liver mitochondria. This is con-
sistent with the data of Wang et al. [14] indicating that ATPSβ is a marker of progression of
steatosis and diabetic complications in rodent models. In contrast, melatonin supplementation
in ob/obmice increased ATPSβ expression; this rise is associated with amelioration of mito-
chondria morphology and reduction of diameter. Moreover, this result is in line with recent
study by Agil et al. [55] in Zucker diabetic rat liver, where melatonin mitigated steatosis and
mitochondria alterations. Furthermore, it is known that mitochondria are important target of
melatonin action [56] and that melatonin has a direct role in mitochondrial homeostasis reduc-
ing oxidative stress and enhancing also ATP production [57–59], these may explain how mito-
chondrial ultrastructural damages, CNX and ATPSβ expressions are restored after melatonin
treatment.
Our data also show that GRP78 and CHOP expressions were high in liver of ob/obmice and
they were reduced after melatonin treatment. These findings were expected in list of the obser-
vations of other colleagues showing that these proteins are essential for proper protein folding
and assembly [60]. It is accepted that the expression of GRP78 identifies the state of ER stress
and CHOP could regulate several apoptotic signaling pathways leading to cellular death. More-
over, proapoptotic CHOP has been reported previously in ob/obmouse liver by Arruda et al.
[52]; but we demonstrate that these changes were hampered by melatonin. This latter finding
may be due to the well established anti-apoptotic effect of melatonin related to the modulation
of intrinsic mitochondrial pathway [61].
Another important finding of this study is that SIRT1 expression and protein level are very
weak in the nuclei of ob/ob hepatocytes and increased after melatonin treatment. In our previ-
ous work [62], we showed that SIRT 1 expression was reduced in murine hepatocytes and in
mice fed a high fructose diet. SIRT1 is an important cellular survival protein and it believed to
promote healthy ageing [63,64]. SIRT1 regulates glucose and lipid metabolism through its dea-
cetylase activity and via its direct and indirect involvement in insulin signaling. Moreover, a
hepatocyte deficiency of SIRT1 induced activation of several systems responsible for causing
damage and decreasing fatty acid oxidation [65]. Remarkably, liver-specific SIRT1 deficiency
causes hepatic glucose overproduction, chronic hyperglycemia and increased oxidative stress.
Importantly, SIRT1 controls the redox system and reduces oxidative stress [18].
We also studied β-catenin expression and observed that it was recovered in ob/obmice after
melatonin treatment. This is strongly correlated with reduced macrosteatosis confirming that
alterations in its activity is associated with the development of NAFLD and other liver diseases,
as reported also by Monga [66]. This is because β-catenin also regulates the expression of genes
that control the metabolism of glucose and nutrients. There are many pathways in which β-
catenin is involved, including Wnt signaling. β-catenin also interacts with transcription factors
such as T-cell factor, forkhead box protein O and hypoxia inducible factor 1α to regulate the
expression of target genes. Moreover, alterations in its activity may contribute to the pathogen-
esis of NAFLD [66].
In conclusion, melatonin promotes several physiological pathways modulating hepatic and,
in particular, liver mitochondrial and ER dysfunctions that are involved in obesity and NAFLD
as a potential treatment for these diseases (Fig 6). This study may help to explain, together with
the evidences of melatonin safety and efficacy, the benefits of melatonin against obesity and
NAFLD. To understand the exact mechanism(s) underlying melatonin diet supplementation
beneficial effects at cellular and molecular levels, broader studies using various (probably low)
dosages of melatonin and varied durations of treatment at different stage of the obesity
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pathogenic process should be considered. Nevertheless, approaches that restore also the proper
function of ER-mitochondria interface may be useful tools in the treatment of multiple meta-
bolic diseases.
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